Cyclacel Limited, with its slogan "Translating cancer biology into medicines," is a pharmaceutical company based out of 46-48 E Smithfield, London, United Kingdom. Founded in 1996, the company operates within the Biotechnology, Health Care, and Pharmaceutical industries. Cyclacel Limited recently secured a significant $8.00M Post-IPO Equity investment on 30 April 2024. This funding injection reflects strong investor confidence in the company's potential to drive innovation and make significant strides in cancer treatment. Cyclacel Limited's focus on translating cancer biology into powerful medicines positions it well to make a significant impact in the healthcare and pharmaceutical sectors.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Post-IPO Equity | $8.00M | - | 30 Apr 2024 | |
Post-IPO Equity | $1.30M | - | 22 Dec 2023 | |
Post-IPO Equity | $14.50M | - | 12 Mar 2021 | |
Post-IPO Equity | $20.00M | - | 21 Apr 2020 | |
Post-IPO Equity | $15.20M | - | 25 Jul 2017 |
No recent news or press coverage available for Cyclacel Pharmaceuticals, Inc..